ImpediMed Limited announced a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex® technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6, 2022 to December 10, 2022 in San Antonio, Texas. The poster, titled Bioimpedance spectroscopy monitoring reduces long-term clinical lymphedema risk includes a Kaplan-Meier analysis of data from the PREVENT Trial to assess lymphedema progression-free survival in breast cancer patients who triggered for subclinical lymphedema and received intervention (n=209). The analysis showed that there were statistically higher rates of lymphedema progression-free survival in patients screened for subclinical lymphedema using L-Dex compared to using tape measure, p = 0.021.

The primary aim of the PREVENT Trial was published in January 2022 and demonstrated that patients with early detection using L-Dex and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.

The primary aim paper also included a risk-adjusted analysis, which showed a significantly consistent benefit of L-Dex monitoring in a large group of patients with key risk factors for breast cancer-related lymphedema including body weight, stage of cancer, type of cancer surgery, lymph node dissection, chemotherapy, and radiation (odds ratios: 0.23-0.39). Today, L-Dex is the only non-invasive, reliable, validated tool to help clinicians identify subclinical lymphedema. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.